Literature DB >> 17917832

Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.

Richard Quek, Wan Teck Lim, Kian Fong Foo, Wen Hsin Koo, Afidah A-Manaf, Han Chong Toh.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917832     DOI: 10.1080/02841860701253060

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  4 in total

1.  Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.

Authors:  Miao-zhen Qiu; Xiao-li Wei; Dong-sheng Zhang; Ying Jin; Yi-xin Zhou; De-shen Wang; Chao Ren; Long Bai; Hui-yan Luo; Zhi-qiang Wang; Feng-hua Wang; Yu-hong Li; Da-jun Yang; Rui-hua Xu
Journal:  Tumour Biol       Date:  2014-02-11

2.  S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.

Authors:  Yu Hong Li; Miao Zhen Qiu; Jian Ming Xu; Guo Ping Sun; Hui Shan Lu; Yun Peng Liu; Mei Zuo Zhong; He Long Zhang; Shi Ying Yu; Wei Li; Xiao Hua Hu; Jie Jun Wang; Ying Cheng; Jun Tian Zhou; Zeng Qing Guo; Zhon Gzhen Guan; Rui Hua Xu
Journal:  Oncotarget       Date:  2015-10-27

3.  Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer.

Authors:  Mohammad Ali Mashhadi; Zahra Sepehri; Ali Reza Bakhshipour; Ali Zivari; Hossein Ali Danesh; Hasan Ali Metanat; Azra Karimkoshteh; Seyed Mehdi Hashemi; Hossein Rahimi; Zohre Kiani
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-10-01

4.  Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.

Authors:  Jingyuan Peng; Chongqing Tan; Xiaohui Zeng; Shikun Liu
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.